3rd ESTRO Forum 2015 lymph nodes and a boost volume including the prostate and seminal vesicles; TPs were generated in simultaneous boost technique. For AP, a progressive engine is used where the user defines prioritized optimization goals for PTV-coverage and dose thresholds and priorities for each organ at risk (OAR). The AP engine automatically creates objectives and required optimization aid structures (OAS), and multiple optimization loops iteratively reformulate and adjust the optimization objectives to meet the goals and further lower dose to OAR with minimal compromise to the target coverage. For manual planning, additional OAS have to be generated by the planner, objectives and priorities have to be adjusted manually for each optimization loop. For plan comparison, various dose and dose volume metrics (D med , D 98% , D 2% V 95% for target volumes, D 2% , D med and V x% for OARs) as well as homogeneity index (HI = (D 2% -D 98% )/ D 50% ) and conformity index (CI Paddick = TV² PI /(PI*TV)) were evaluated. Efficiency of the plan optimization procedure was estimated by means of total time required to create a TP. Results: PTV coverage V 95% was 93.5±3.5% and 97.9±1.3% and boost coverage was 95.5±2.0% and 98.3±1.7% for MP and AP, respectively. Homogeneity index for the PTV was 0.14±0.02 and 0.12±0.02 and for the boost it was 0.11±0.02 and 0.07±0.02 for MP and AP, respectively. CI was 13% and 16% higher in manual plans compared to automatic plans for PTV and boost, respectively. D med and D 2% for bladder and femoral heads showed no particular differences between manual and automatic plans. However, considerable deviations in D med were found for the rectum (27.8±4.7Gy vs 33.3±5.8Gy for MP and AP, respectively) and intestine (25.2±7.5Gy and 22.8±8.2Gy for MP and AP, respectively). Further, V Tissue30% representing tissue outside the target volumes received 36% more dose in AP compared to MP. The time to create a treatment plan was <1 hour for MP and >2 hours for AP. Conclusions: Automatically generated TPs improve target coverage and homogeneity at the cost of slightly decreased conformity when compared to manual TPs. OAR sparing is mostly comparable, higher dose contribution to normal tissue outside the PTV was found for AP. Since higher low dose volume was detected in normal tissue for AP plans, each TP needs to be evaluated by an experienced planner and adapted when necessary. Prioritized optimization goals in AP need to be carefully established and the overall time required to create a plan remains to be optimized.
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Materials and Methods:
Preparing and optimizing a model for clinical use consisted of 2 stages: training the dose prediction algorithm using a library of approved clinical plans; and defining how dose predictions were used to generate patientspecific objectives in the IMRT optimizer. Structures and dose distributions from previously-treated prostate patients were used to train the model. Sufficient plans, 41 initially, were added as directed by initial statistical analyses to ensure the model was adequately trained for all structures. Analysis of potential outliers was then carried out to exclude patients that would adversely influence the model outcome. 3 types of model were created: i) all plans included; ii) the most extreme outliers were excluded (e.g. patients with prosthetic hips); iii) all patients identified as outliers by RapidPlan were excluded. The resulting models were then used to generate plans for 5 patients who had not been included in the modelling process. Plan optimization objectives consisted of a line objective and maximum dose point objective for each OAR, and minimum and maximum point objectives for all PTVs. Comparisons of generated plans with corresponding clinical plans were carried out to indicate required changes to the models. Model parameters were then iteratively adjusted until plan quality converged with that of the clinical plans for the test patients. Results: A number of changes to the initial model were required. These included setting the normal tissue objectives from the default to those used clinically in local IMRT protocols while maintaining the default smoothing parameters set. For the final version of the model, plans created using the RapidPlan model were similar to the equivalent plans devised by experienced planners and used clinically ( Figure 1, Table 1 ). In some cases PTV coverage was slightly reduced in the superior and inferior edges for RapidPlan plans compared with clinical plans. OAR doses were similar for both RapidPlan and clinical plans. No significant difference was seen between the performance of models i), ii) and iii). 
Conclusions:
This study has highlighted the potential of the 3rd ESTRO Forum 2015 S775 RapidPlan software in generating clinically acceptable plans in a semi-automated manner for 5-field IMRT prostate treatments. Statistical guidance on exclusion of outliers appears somewhat conservative -inclusion of all available good quality plans should improve the scope and robustness of the model.
EP-1433
Treatment planning system geometric tools perfomances study with Qualiformed software A. Dupas 1 , D. Autret 1 1 Institut de Cancérologie de l'Ouest, Medical Physics, Angers, France Purpose/Objective: The aim of this study is to evaluate the geometric performances of the treatment planning system (TPS) in external radiotherapy in order to identify its limits. Materials and Methods: Eclipse (Version 10) TPS was evaluated with the quality control software Digibox (version 2.2). Digibox has a control points database, in which the operator selects some to create a set of control points that will be identified as a new quality control. For each control point of the quality control, Digibox prepares a digital test object (DTO) that automatically transfer to the TPS via the network. The operator then performs on the TPS the geometrical operation he wants to test. The test result is then returned to Digibox that analyses by comparing it with a theoretical result DTO. This study is composed of two sections. Section 1 deals with the beams display. Section 2 is about the definition of contours, margins, isocenter and the beams conformation. Results: 152 elementary geometrical operations were performed for a period of 14 hours of work, not included import and export times. The results of section 1 show no significant difference. The tests were: rotation of the collimator, beam angles, filed sizes and beam divergence. The results of section 2 showed however some important differences, especially on 3D margins for volumes with variable sections and small structures (<12 cm3), and the automatic positioning of the isocenter in complex structures. Minor discrepancies were identified on the conformation of the beams and jaws, the automatic contouring, and calculation of the volume of a structure showed less variation. Conclusions: Using Digibox, we could highlight two types of problems which one particularly concerns the stereotactic technique. This digital evaluation is an asset and can be used when an upgrade of the TPS is performed or to compare the performances of two TPS in the same department. Finally, the study of the definition of the bolus, the blocks, the distances calculation and the zoom tool are not yet possible with Digibox.
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Pre-clinical validation of RapidPlan, a knowledge-based DVH estimation for optimising lung or prostate plans A. Fogliata 1 , P. Navarria 2 , G. Nicolini 1 , M. Scorsetti 2 , A. Clivio 1 , E. Vanetti 1 , F. Belosi 1 , L. Cozzi 1 1 Oncology Institute of Southern Switzerland, Medical Physics, Bellinzona, Switzerland 2 Humanitas Clinical and Research Center, Radiotherapy and Radiosurgery Dept, Italy Purpose/Objective: To evaluate the performance of a knowledge-based DVH estimation constraints, namely RapidPlan, for optimising volumetric modulated arc therapy (RapidArc) applied to advanced lung cancer and to low risk prostate carcinoma patients. Materials and Methods: Two sets, one for lung and one for prostate cases, each of 27 previously treated patients, were selected to configure and train models for the estimation of dose-volume constraints to use in the optimization process. The models were subsequently validated on the same sets of 27 plans each (closed-loop) and on further two sets each of 25 patients not used for the training (open-loop). The two site groups differ mainly in the homogeneity of the characteristics: -Advanced lung cancer group: in-homogeneous dose prescription (50-70 Gy), wide variety of target volumes (67-1193 cm 3 ), two partial arc geometry -Low risk prostate group: homogeneous dose prescription (78 Gy), modest variability of target volumes (80-421 cm 3 ), single full arc geometry Analysis was based on DVH and statistics comparison between the RapidPlan and the original clinically accepted plans. Second endpoint was the evaluation of the pass-fail analysis for the two groups of plans based on consolidated criteria as following. For lung cases: D 99% >95%(90%) and D 1% <107% for CTV(PTV); mean<20Gy for ipsilateral, mean<15Gy and V 20Gy <20% for contralateral lung; D 1cm3 <45Gy to spine; V 45Gy <30% and V 50Gy <20% for heart; D 1cm3 <70Gy and V 30Gy <30% for oesophagus. For prostate cases: D 99% >95% and D 1% <107% for PTV; V 70Gy <10%, V 60Gy <40% and V 50Gy <50% for rectum; V 70Gy <30% and V 60Gy <50% for bladder; D max <50Gy for femoral heads. Results: Average differences between the RapidPlan and the original plans of some dosimetric values are reported in the table (p values in parenthesis), where negative values indicate a superior mean plan quality of RapidPlan (the opposite for D 99% for target). A significant improvement is shown for RapidPlan plans in both closed-and open-loop validations.
In the pass-fail analysis, the rate of criteria not fulfilled was reduced in the lung patients group from 11% to 7% in the closed-loop and from 13% to 10% in the open-loop studies; in the prostate patients group it was reduced from 4% to 3% in the open-loop study. Conclusions: Plans were optimised using a knowledge-based model showed dosimetric improvements when compared to the original benchmark data, particularly in the sparing of organs at risk. The data suggests that the new engine is
